The global market for RNA interference (RNAi) was $145.2 million in 2007 and is expected to reach $174.5 million by the end of 2008. It should reach $3.6 billion by 2013, a compound annual growth rate (CAGR) of 83.4%. This report contains:

• Descriptions of various RNA interference (RNAi) technologies including research and development tools, diagnostics, therapeutics and agricultural applications.
• The current global market status of the RNAi industry, with trends and forecasts for growth over the next 5 years
• Analysis of the RNAi industry on a worldwide basis, both from a market and application perspective
• Discussion of state-of-the-art RNAi technologies and their future commercial potential
• Profiles of the main companies in the RNAi field.

The U.S. market for environmental biotechnology products for waste treatment will increase from $166.8 million in 2007 to an estimated $180.3 million by the end of 2008. It should reach $261.3 million by 2013, a compound annual growth rate (CAGR) of 7.7%. This report contains:

• Descriptions of various types of environmental biotechnology products for waste treatment including microbial blends, nutrients, enzymes and microbes.
• The current market status of environmental biotechnology products for the waste treatment industry, with trends and forecasts for growth over the next 5 years
• Analysis of the environmental biotechnology industry on a worldwide basis, both from a market and application perspective
• Profiles of major product manufacturers.

The global market for monoclonal therapeutic and diagnostic antibodies increased from $26 billion in 2006 to an estimated $31 billion by the end of 2007. It should reach $56 billion by 2012, a compound annual growth rate (CAGR) of 13%. This report contains:

• Descriptions of various types of monoclonal therapeutic and diagnostic antibodies in terms of their history in medicine, their types and technology categories
• The current market status for monoclonal therapeutic and diagnostic antibodies, trends and forecasts for growth over the next 5 years
• Technological issues including the latest trends and a thorough patent analysis
• Analysis of the monoclonal therapeutic and diagnostic antibodies industry on a worldwide basis, both from a market and application perspective
• Discussion of government support in major regions of the world.

The global market for industrial enzymes increased from $2.2 billion in 2006 to an estimated $2.3 billion by the end of 2007. It should reach $2.7 billion by 2012, a compound annual growth rate (CAGR) of 4%. This report contains:

• Descriptions of various technical enzyme applications including detergent, textile, pulp and paper, leather, and miscellaneous chemicals; also, food applications including confectionery and sweeteners, dairy, fruit and vegetable processing,, and animal feed
• The current market status of enzymes, trends and forecasts for growth over the next 5 years
• Analysis of the enzymes industry on a worldwide basis, both from a marketing and application perspective
• Discussion of emerging technologies with a thorough patent analysis
• Information about major players and their contributions to the enzymes industry.

The global market for drug discovery technologies increased from $20.2 billion in 2006 to an estimated $22 billion in 2007. It should reach $32.5 billion by 2012, a compound annual growth rate (CAGR) of 8.2%. This report contains:

• Descriptions of various drug discovery-related products including bioanalytical instruments, high throughput screening, informatics and microarrays
• The current market status of drug discovery technologies, trends and forecasts for growth over the next 5 years
• Discussion of new methods of research important to the market including compound discovery, compound optimization, efficacy testing in vitro and in vivo, toxicology testing, pharmacokinetics, and stability testing
• An analysis of patents and their importance to the industry.

The global market for nanoparticles used in biomedical, pharmaceutical and cosmetic applications increased from $170.7 million in 2006 to an estimated $204.6 million in 2007. It should reach $684.4 million by 2012, a compound annual growth rate (CAGR) of 27.3%. This report contains:

• Descriptions of various types of nanoparticles including nanoparticulate ceramics, metals, alloys, and semiconductors in the form of dry powders, liquid dispersions, coatings and bulk materials
• The current market status for nanoparticles, trends and forecasts for growth over the next 5 years
• Discussion of organic nanoparticles such as lipids and dendrimers that are expected to play a significant role in future applications
• Analysis of nanomaterials-related patents issued during the past 2 years
• Profiles of major and minor companies working with nanoparticles.

The global market for biomarkers increased from $4.8 billion in 2006 to an estimated $5.6 billion by the end of 2007. It should reach $12.8 billion by 2012, a compound annual growth rate (CAGR) of 18%. This report contains:

• Descriptions of various types of biomarkers including genomics, proteomics, bioformatics and metabolomics
• The current market status of biomarkers, trends, and forecasts for growth over the next 5 years
• Technological issues including the latest trends and findings in different therapeutic research areas
• An examination of the regulatory role of different federal agencies in U.S., Europe and the rest of the world that play an active role in biomarker discovery research
• Analysis of the biomarkers industry on a global basis, both from a market and application perspective.

The global market for biochips increased from $1,637.5 million in 2006 to an estimated $2,115.6 million by the end of 2008. It should reach $3,840.7 million in 2013, a compound annual growth rate (CAGR) of 12.7%. This report contains:

• Descriptions of various biochips including current and potential applications
• The current market status of biochip products, trends and forecasts for growth over the next 5 to 10 years
• Technological issues, including the latest advances
• A discussion of driving forces in the biochip industry on a global basis, including large-scale integration, research initiatives and drug discovery
• An examination of biochip companies and industry alliances.

The total U.S. sales of media, sera, and reagents for biotechnology was $979 million in 2005 and almost $1.1 billion in 2006. At a compound annual growth rate (CAGR) of 8.9%, this market will grow to reach more than $1.6 billion in 2011. This report contains:

• An overview and analysis of the major types of media, sera and reagents used in biotechnology
• Global market forecasts for the industry, including current and historical data as well as 5-year market projections to 2011
• Review of the latest trends in technology, the latest important discoveries, and ideas and estimates for the future
• A detailed analysis of important patents within the past several decades
• Company profiles for the major industry players.

The global market for epigenomics was $161.8 million in 2005 and $263.2 million in 2006. The market will cross $385 million by 2007 and at a compound annual growth rate (CAGR) of 60.4% will reach nearly $4.1 billion by 2012. This report contains:

• The major epigenomics technologies and developments that are likely to become commercialized within the next five years
• Provides detailed market information for the global epigenomics market including historical data, current information, and projections to 2012
• Offers a focus on particular applications of epigenomics, including research tools, diagnostics, drugs, and cloning/tissue engineering
• Discusses the market in terms of important medical applications such as biomarkers, cancer therapy, and reproductive technology
• Offers a detailed review of important patents and technologies
• Profiles the most competitive businesses in the industry.

The U.S. market for protein separation systems is estimated to be valued at almost $3.0 billion in the base year, 2006. This market is expected to grow with an average annual growth rate (AAGR) of 11.1% and cross the $5.0 billion by the year 2011. This report contains:

• The U.S. market for separation systems of commercial biotechnology broken down into five segments: liquid chromatography, centrifugation, membrane filtration, electrophoresis and niche separations
• Market trends, historical data, and five-year projections to 2011
• A discussion and review of important technology and the latest technological advancements in the industry
• Lists and analysis of important and upcoming patents
• Profiles for the top players within the industry.

The total global market for protein drugs was $47.4 billion in 2006. The market will reach $55.7 billion by the end of 2011, an average annual growth rate (AAGR) of 3.3%. This report contains:

• Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials
• Market trends and five-year forecasts with projections through 2011
• Examination of current technologies underlying the market and details the effects of new technologies on this market
• Profiles of the major companies involved in the production and modification of protein drugs.
• An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.

Global revenues for enzyme inhibitors were $32.1 billion in 2005. At an average annual growth rate (AAGR) of 5.1%, this market will cross $43 billion by 2011. This report contains:

• The major current and emerging therapeutic markets for enzyme inhibitors used in human therapeutics,
• A discussion of the biochemistry for enzyme inhibitors and classes of enzyme inhibiting products with broad current or potential therapeutic applications or large markets,
• A synopsis of more than 100 enzyme inhibitors, including those currently marketed and those in Phase II or later development,
• An overview of the leading indications for available and emerging enzyme inhibitors. These include selected indications for asthma and chronic obstructive pulmonary disease (COPD), cardiovascular diseases, erectile dysfunction, gastrointestinal disorders, hepatitis B virus infection, hepatitis C virus infection, herpesvirus infections, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and rheumatoid arthritis and related inflammatory diseases,
• Forecasts for the global market, through 2011,
• Company Profiles emphasizing companies that lead the pharmaceutical and biotechnology industry in the research and development of enzyme-inhibiting drugs.

The area most likely to see strong growth in the next five years is the one involving collaborations between large and small companies. Such collaborations were worth $13 billion in 2005, will increase to $14.4 billion in 2006 and reach $22 billion in 2010. This report:

• Analyzes the newly emerging industry in proteomics.
• Provides an overview of the market and a brief discussion of relevant scientific principles.
• Discusses current and future investment trends for the U.S. and the importance of each new method of research to the overall market.
• Analyzes patents and their importance to the industry.
• Considers investment by angel investors and venture capitalists, collaborations and mergers and acquisitions.
• Examines the relative merits of systems biology, a new approach and potential "next big thing" in the industry.
• Presents appendices that contain directories of companies and investors, as well as profiles of companies given significant coverage in the report.

The global market for plant-derived drugs was worth an estimated $18 billion in 2005. BCC expects this figure to grow to nearly $19 billion in 2006 and more than $26 billion by 2011, at an AAGR of 6.6% between 2006 and 2011. This report:

• Identifies and classifies the plant-derived drugs that have been commercialized to date.
• Analyzes the historical and current volume and value of shipments of each of these drugs in specified geographical markets.
• Identifies and evaluates the impact of factors that will drive future demand for plant-derived drugs.
• Describes plant-derived drugs that are currently in the clinical testing or approvals stage and assesses the probability that they will be commercialized successfully in the next 5 years.
• Contains forecasts for the global volume and value of plant-derived drug shipments and their markets through 2011
• Identifies the leading manufacturers of plant-derived drugs and the firms that may become important players in the next 5 years.

In vitro and in vivo diagnostics account for nearly 87% of a total market of more than US $8.0 billion. This market will show a steady annual growth of around 6.6% for the next five years. This report:

• Assesses technological developments and how they will impact the industry
• Identifies the driving forces for demand
• Makes available the most current and reliable information on consumption of probes and related chemicals in enzyme immunoassay
• Estimates the global supply and demand scenario broken down by applications and regions
• Assesses the growth rate in demand
• Projects demand and supply by applications and regions up to 2010
• Profiles major companies involved in this business and their market shares.

The U.S. market for therapeutics and diagnostics for genetic diseases reached $4.8 billion in 2005 and is expected to grow at an average annual growth rate (AAGR) of 8.7%, reaching $7.3 billion by 2010. This report:

• Examines common genetic diseases that result from a single mutation, namely: Cystic Fibrosis, Down Syndrome, Duchene and Becker Muscular Dystrophy, Fragile X Syndrome, Hemophilias, Polycystic Kidney Disease, Sickle Cell and related anemia, and Thalassemias.
• Outlines the genetic causes, common mutations, diagnostic methods and disease pathology for each of the most frequent monogenic diseases.
• Discusses current and emerging treatments and analyzes the markets for each, with forecasts projected through 2010.
• Profiles major companies and their market shares and evaluates significant patents.
• Presents an outlook on future directions and challenges.

The worldwide market for kinase inhibitors for clinical use will reach $4.63 billion in 2005 and will rise at an average annual growth rate (AAGR) of 20.6% to $11.8 billion by 2010. The report contains:

• A thorough review of the technologies employed in the kinase inhibitor
• Analysis of the evidence of efficacy and technical limitations of each kinase inhibitor type in clinical use
• Analysis of the current market status and growth forecasts through 2010 for each kinase inhibitor
• Examination of the potential for additional novel applications
• Discussion of the role of government regulations, recent patents and factors affecting the industry worldwide
• Analysis of how the development of new kinase inhibitors is translating into new medical therapies for specific disease targets.

The worldwide market for stem cell, cytokine and growth factor therapies is estimated at $12.7 billion in 2005 and, rising at an average annual growth rate of 10.3%, is expected to reach $20.7 billion in 2010. The report contains:

• An overview that introduces the various kinds of stem cells, gives definitions, and discusses political, regulatory aspects, and the major developments of 2005 including the retraction of previously published South Korean stem cell research results
• Analysis of applications including current and potential cytokine and cell therapies with forecasts through 2010
• A discussion of current products as well as many that are still in clinical trials
• An industry structure analysis including companies in the field and their focus
• Profiles of individual companies, and includes the names of key officers.

The worldwide market for therapeutic and diagnostic antibodies is estimated at $15 billion in 2005 and will rise at an average annual growth rate of 11.5% to nearly 26 billion in 2010. The report contains:

• A discussion of the importance and advantages of antibody-based products, patent issues and applicability
• Analysis of antibody technology, research and production, and the types of antibodies used as therapeutics or diagnostics
• A synopsis of more than 100 monoclonal and polyclonal antibody drugs and diagnostic imaging products currently marketed and those in Phase II or later development
• Comparative product and sales analyses, including current and forecasted sales through 2010 by individual product, target and technology, as well as worldwide market size and growth estimates
• An overview of the leading indications for available and emerging antibody-based therapeutics and diagnostics
• Profiles of leading companies and those with emerging products or technologies.

The worldwide value of bioinformatics is expected to increase from $1.02 billion in 2002 to $3.0 billion in 2010, at an average annual growth rate of 15.8%. The report contains:

• Technological descriptions of, and patenting trends in bioinformatics
• Examination of the economic environment impacting the deployment of bioinformatics
• Analysis of market factors and the worldwide potential of bioinformatics through 2010
• Analysis of the basis of products, applications and geographic presence
• Discussion of other influential factors such as R&D spending in the pharmaceutical sector, the growth of agrobiotechnology, and the expanded use of microbial genomics.

The total U.S. market for new therapeutics and diagnostics for women's disorders was estimated at more than $25 billion in 2004 and is expected to reach nearly $41 billion in 2009, rising at an average annual growth rate of 10.3%. The report contains:

• Identification of the markets in general segments:
     - Autoimmune diseases
     - Women's cancer
     - Gynecological diseases and infections
     - Kidney and urological diseases and infections
     - Reproductive-related therapies and diagnostics
     - Rheumatoid arthritis and osteoporosis
• Detailed information based on product categories and their use
• U.S. market forecasts through 2009
• Competitive analyses and leading company profiles.

Projected sales for the worldwide DNA sequencing and proteomics markets are expected to rise at an AAGR average annual growth rate of 17.6% from $7.8 billion in 2004 to $17.5 billion in 2009. The report contains:

• A historical overview of the industry and a description of the market structure
• Identification of the key market industrial players along with a listing of government and university research centers
• Reference sources, patents and key R&D issues
• Product forecasts through 2009, including DNA sequencing and amplification equipment, microarrays, analysis platforms, reagents and probes, software analysis tools, databases and proteomics research products
• Appendices including lists of conferences, patents and references.

The global market for biosensors and other bioelectronics is projected to grow from $6.1 billion in 2004 to $8.2 billion in 2009, at an average annual growth rate of about 6.3%. The report contains:

• Definitions covering the industry and technologies
• Milestones in the development of biosensors and bioelectronics
• Existing biosensor and bioelectronic technologies and technologies under development
• Detailed discussion of intellectual property and patent portfolios
• Analysis of applications and end-user segments with the greatest commercial potential through 2009
• Analysis of biosensor and bioelectronic market trends, through 2009
• Industry structure and market shares.

The worldwide market for amino acids for synthesis is projected to rise at an average annual growth rate of 7% through 2009 from $713 million to $1 billion. The report contains:

• Identification of synthesis applications of amino acids in the biotechnology and pharmaceutical industries
• A review of current supply sources of amino acids for synthesis applications
• Quantification of the dollar amount of amino acids being used for these applications
• Market forecasts through 2009
• An overview of amino acid synthesis technology
• Profiles of leading synthesis companies.

The total worldwide market for therapeutic vaccines was $8.1 million in 2004. With increased product introductions, this market is expected to top $4 billion in 2010. The report contains:

• An emphasis on companies poised to introduce products during the forecast period
• Analysis of how these introductions will play out in terms of the competitive environment
• Focus on how new products and technologies are likely to define market leaders in the therapeutic vaccine arena
• Forecasts by product segment and indication through 2010, including supporting analyses
• Profiles of companies projected to have therapeutic vaccine products on the market during the period.

The global market for industrial enzymes is estimated at $2 billion in 2004 and is expected to rise at an average annual growth rate of 3.3% to $2.4 billion in 2009. The report contains:

• Coverage of three major application sectors: technical, food and animal feed enzymes
• An overview and assessment of the global scenario for industrial enzymes
• Analysis of the markets for industrial enzymes and their future growth by sector and region with forecasts to 2009
• Assessment of technology developments
• Identification of the driving factors for demand
• Profiles of the major players and their contributory roles.

Global revenues from biotech-enabled cancer therapies are expected to rise at an AAGR (average annual growth rate) of 14.5% from $15 billion in 2003 to more than $29 billion in 2008. The report:

Identifies all major biopharmaceuticals that were in clinical trials to treat cancer as of the spring of 2004

Describes these biopharmaceuticals and their proposed mechanisms of action

Identifies and profiles companies involved in developing biopharmaceuticals

Discusses regulatory policies that affect the development of biopharmaceuticals

Estimates current markets for biopharmaceutical drugs and project future sales five years out, through 2008.

The current worldwide market for therapeutics from transgenic sources is zero, is expected to exceed $1 billion in 2008 and reach $18.6 billion in 2013. The report contains:

• Discussion of the transgenic species and technologies involved in the production of human therapeutics
• In-depth discussion of individual products currently in development
• Estimates of current markets for protein based products with forecasts through 2013
• Discussion of the impact of transgenically produced protein drugs and vaccines on the marketplace as well as the regulatory environment
• Profiles of companies focusing solely on the development of these products as well as companies that are including such products in a diverse product pipeline.

The total U.S. market for chiral technology is rising at an average annual growth rate of 8.8% and expected to exceed $1.8 billion in 2008. The report covers:

• The synthesis, separation and analysis of chiral technology
• Each technique and technological issue including the latest trends and developments
• Manufacturers, new products and sales estimates and market share information
• Markets with projections through 2008
• Regulations set by government agencies and recent approvals of chiral drug products
• Significant in chiral technology patents.

The total market for DNA microarrays and materials is rising at an average annual growth rate of 13.4% and is expected to just exceed $1 billion in 2007. The report contains:

• An industry structure chapter, detailing the makeup of the firms that produce Microarrays and those that produce materials used in microarray production, along with selected company profiles
• An extensive technology overview, covering the relevant technology of DNA microarray production and materials, along with comparisons of various technologies
• A thorough description of the available products for DNA microarrays, and the materials used to produce them
• A concluding market applications section, discussing some of the relevant trends in the use and costs of DNA microarrays
• Forecasts for microarrays and materials through 2007.

Sales of protein drugs are projected to reach $71 billion in 2008 as the markets grows at an average annual growth rate of 12.2% through the forecast period. This report provides:

• Coverage of proteins that are used for therapeutic purposes
• Analysis of protein-based drugs in clinical trials and, like all drugs, their historically high failure rates
• Unbiased market forecasts for the period through 2008
• Examination of current technologies underlying the market and details the effects of new technologies on this market
• Profiles of the major companies involved in the production and modification of protein drugs.

Biotech separations was a $2.1 billion business in the U.S. in 2003 and is projected to rise to $3.6 billion in 2008, at an average annual rate of 11.0%. The timely BCC report:

• Tracks significant advances with current market applicability
• Discusses emerging technologies with nearterm market impact
• Analyzes cornerstone technologies, including chromatography, electrophoresis, centrifugation and membrane filtration
• Details current and projected market values through 2008 for systems and aftermarket sales
• Delves into novel techniques with possible future viability
• Analyzes U.S. market trends and economic indicators
• Evaluates major players in the industry.

The U.S. market is expected to rise at an average annual growth rate of 13.1% and reach $1.7 billion by 2008. The report provides coverage of:

• The major types of media, sera and reagents in cell culture used in the biotech industry
• Technological issues and the latest trends and developments
• Existing and new product lines
• The growth by acquisition strategies and the collaborations by companies to increase sales and develop better and newer products
• Sales estimates, market projections through 2008 and market share information
• Government regulation.

The worldwide market for genomics technologies utilized in the processes of drug target screening, drug target identification and drug target validation is expected to reach $13.6 billion by 2007. This report provides coverage of:

• Why genomics-based drug target validation is so critical
• Definitions of the components used in genomics, namely bioinformatics, comparative/functional genomics, high-throughput screening and proteomics
• Drug target validation technologies and services including current status, obstacles, opportunities
• Companies, their technologies and profiles; industry structure, regulatory issues, role of patents
• Five-year market forecasts for genomics based products, services and applications.

Sales of drugs for immune diseases will grow at an average annual growth rate of 8.4% through 2007. This analysis includes:

• Discussions of diseases caused by disorders of the immune system
• Profiles of small-molecule and biologic therapies in use now and by the end of 2007
• Examination of promising drugs in the early stages of development
• Break out of the major medical markets for immune diseases
• Profiles of leading companies.

The potential market for antisense therapeutics in 2007 is estimated to be more than $3.15 billion. This report includes:

• Antisense technologies review
• Discussion of antisense therapeutic applications: cancer, coronary heart disease, type 2 diabetes, immunological disorders, infectious diseases, polycystic kidney disease and retinal disorders
• Analysis of the markets for antisense therapeutic applications
• Profiles of 18 companies and their antisense therapeutic products
• Antisense industry structure.

Total worldwide sales of plant-derived drugs in 2002 are estimated at $13.7 billion. Sales are projected to increase at an average annual growth rate of 6.4% through 2007. This BCC study:

• Provides an analysis of the industry and markets by region, technology, category of
• Drug and medical application
• Analyzes the current and future volume and value of classified plant-derived drugs through 2007
• Evaluates market drivers, as well as technological, environmental, legal/regulatory and socioeconomic factors.
• Forecasts the market for plant-derived drugs in the clinical testing or approval stages
• Identifies leading manufacturers along with the firms that may become important players.

The global marine biotechnology market is projected to surpass $3.2 billion by 2007 with the non-U.S. segment comprising bulk of the market. This report describes the U.S. marine biotechnology industry and the emerging market marine biotechnology products and services. Specific topics covered include:

• Major types and applications of marine biotechnology
• Industry structure
• Market size and segmentation, including historical data on sales by product/service and end-user segment
• Market drivers
• Detailed market projections through 2007
• User requirements and success factors
• Competition and market shares
• Observations and conclusions regarding the future of the marine biotechnology industry.

The overall BRM market is projected to have an average annual growth rate (AAGR) of about 13% through 2007, reaching nearly $30 billion. This report covers:

• Definitions of the types of BRMs and their effects on the immune system
• The market and trends of available and emerging BRMs
• Leading indications in development for anemia and bone marrow/stem cell transplantation, cancer and infectious diseases, inflammatory diseases and multiple sclerosis
• Synopsis of products, and sales analyses of all the leading BRM drugs
• Worldwide market size and growth estimates for the BRM drug categories
• The market potential of generic biologic products including the leading BRMs
• Company profiles.

The market for antibody products was estimated at nearly $5 billion in 2001, with nearly $3 billion contributed by monoclonal antibodies. Some analysts project the antibody market will achieve sales of $15 billion to $25 billion by 2010. Polyclonal antibody products continue to enter the market but do not represent the exciting technology and market opportunity that monoclonals do. The sudden surge of genomics technology assures that the monoclonal antibody product market will continue to grow at astounding rates. This report analyzes and assesses therapeutic and in vivo diagnostic imaging applications of antibodies in human medicine. Included in this report are analyses of monoclonal and polyclonal antibody products as well as summaries of antibody products in Phase III or later development. Market projections are provided for selected products and for the monoclonal and polyclonal drugs and diagnostics sectors, through 2007. Technology issues and breakthroughs as well as industry trends are also discussed. Profiles are provided for leading biotechnology and big pharma companies involved in the antibody market as well as for companies developing innovative products not yet launched.

This in-depth study analyzes the markets for biosensors and bioelectronics. Recent advances due to sequencing of the human genome and rapid progress in microcircuitry have served to position this field on the verge of a major explosion in growth. This study looks at the currently marketed technologies, focusing on the categories of application in Agriculture, Food and Fermentation Monitoring, Nanocomputers and Nanotechnology, High Throughput Screening, and Medical and Forensics technologies. An analysis of the current thought leaders in each category of application and a market analysis of current and forthcoming technologies are provided in terms of market share. Public perception and public policy and their effect on regulation of these technologies are examined, particularly as it affects the Food and Medical industries. In addition, growth potential is given for both the current and the emerging technologies for the period from 1999 to 2006.

This in-depth study analyzes commercial developments in therapeutic enzyme inhibitors and receptor blockers. This $75 billion market is undergoing rapid change as new technologies such as genomics, proteomics, high-throughput screening, rational drug design, and combinatorial chemistry are being integrated into drug development and discovery. These technologies are expanding the number of drugs in clinical testing, as well as bringing completely new classes of drugs to market. The study looks at these technologies and explains their effect upon the market for inhibitors and blockers. It then makes detailed market forecasts for the period through 2006 and profiles the major companies involved in blockers and inhibitors.

As many organizations are attempting to find cost effective and efficient means of treating both organic and toxic waste, biotechnology promises to offer less expensive solutions for degradation and remediation of waste through natural microorganism and enzyme products. In this report, professionals in both waste and biotechnology industries will find comprehensive data concerning these biotechnology products for use in waste treatment applications including major market share participant information, analysis of product sales and application end-uses. The historical and current significance of government regulation, patents, and R&D will be reviewed with regard to their vital role in affecting the market dynamics, with special emphasis on future product sales. Data will include international markets including U.S. exports information. Market forecasts are projected for the 2001 to 2006 time frame.

This report focuses on the use of cells as medical therapy. This includes, for example, the replacement of the blood and immune systems with blood stem cells, the use of neural stem cells to treat neurodegenerative systems, the use of mesenchymal stem cells to repair bones and joints, liver stem cells for liver failure, and the potential use of "therapeutic cloning" to repair other tissues. This report is necessary and timely because of the rapid advances that have been made in the field - cell therapies in the pipeline have the potential to replace many of the pharmaceuticals currently marketed to treat chronic diseases, like Parkinson's disease and diabetes. Companies involved in stem cell therapies are profiled and markets are estimated for these therapies through 2005.

Proteomics is an emerging field that has developed in the wake of genomics. Its goal is to understand protein expression at the cellular level, and apply this information to scientific and medical problems. For example, compared to healthy cells, how does influenza virus infection affect the total protein output? Are any of the proteins expressed only in the infected cells suitable targets for new antiviral drugs? This approach also applies to cancerous cells, and cells from patients with degenerative diseases and many other conditions. New technologies like protein chips and capillary electrophoresis are emerging to serve proteomic studies, and more mature technologies like 2-D electrophoresis, mass spectroscopy, and nuclear magnetic resonance spectroscopy are being adapted for protein studies, and in some cases, for high throughput uses. Bioinformatics applications are constantly being developed to analyze the data produced by all of these technologies. This BCC study examines how proteomics technologies have affected basic research and pharmaceutical research, and how they are likely to affect research in the near future. It also analyzes how proteomics technologies are developing, and examines new companies that are likely to make substantial contributions to the field. An important part of the report analyzes instruments that are vital to proteomics studies. Sales and spending projections through 2006 are included.

As the human genome-sequencing project nears completion and other organisms' genomes are sequenced, the number of known proteins increases. Many proteins are currently being used and will be used as diagnostic tools in immunoassays. Immunoassays are used in a variety of applications: medical diagnostics, infectious disease testing, drug testing, home use, hormones, veterinary diagnostic, cancer, tissue typing, research, food testing, environmental testing, industrial chemicals, plant disease diagnostics, and biotechnology products testing. Enzyme-linked immunosorbent, chemiluminescent, fluorescent, radio-labeled, and immunoprecipitation are some of the old and new immunoassay technologies being used. New immunoassay technologies are also being developed. Since the number of known proteins and the potential number of immunoassays are increasing, it is interesting to analyze the current and developing immunoassay technologies and markets.

Angiogenesis- the development of blood vessels -is an area of much activity and promise. The blocking of angiogenesis is a quickly advancing strategy in the treatment of cancer, inflammatory and dermatological diseases as well as disorders of the eye. The stimulation of angiogenesis is under investigation as a means of replacing blood vessels in the heart and peripheral arteries that have become blocked. In 1998, approximately three dozen companies were known to be investigating angiogenesis regulations and in 2001, more than 200 biotechnology, genomics and pharmaceutical and medical companies were involved in research and development programs focusing on angiogenesis. The report provides an in-depth look at the technologies and products in clinical trials and earlier development, disease applications, potential hurdles to market launch, estimated launch dates, impact on currently used therapies and the competitive landscape. Market projections from 2001 through 2006 for angiogenesis inhibitors and stimulators are provided as well as comprehensive coverage on companies involved in angiogenesis regulation, their products and market strategies.

New methods for drug discovery and delivery are receiving considerable attention in the pharmaceutical industry and in the media. Trial-and-error discovery methods have been replaced by focused combinatorial synthesis, high throughput systems, and other advanced systems. These new methods have produced agents that have entered clinical trials. As a result of the new technologies, costs and development times are falling, and knowledge about each new agent's mode of action has increased. This updated BCC study examines how the new drug discovery technologies have affected costs and drug development times. It also analyzes how new screening technologies, DNA microarrays, and increasingly sophisticated instruments will affect pharmaceutical discovery. An important section of the report analyzes market sizes and market growth for each technology. The report also includes interviews with executives in the instruments industry and the combinatorial chemistry industry.

The U.S. amino acid market will likely surpass $1.5 billion by 2005. Annual growth should be 3.3% on average per year (AAGR) while individual amino acids could see growth spurts. This study focuses on three commercial amino acid markets:

• animal feed supplements
• flavoring and nutritional additives for human food
• specialty uses including medical, therapeutic, research and industrial applications.

This report further analyzes the products, applications, technology, international aspects, industry structure and profiles of key companies/organizations involved in the supply of advanced novel separations systems.

The worldwide market for microarrays, scanners, arrayers and microfluidics is projected to approach $1 billion by 2001, with strong growth which is likely to continue for several years, unlike typical markets at the beginning of their life cycles which mature in two to three years. Approximately 60% of the market is thought to be in the U.S., 30% in Europe, and the remaining portion in the Far East. This report describes the world microarray biochip market, including related arrayers and scanners, as well as the market for microfluidics, or lab on a chip. It explores the revenue growth rates of the product segments, points out the market leaders and product innovators, explains the uses of the technology and gives industry predictions of the market size worldwide in three to five years. Any company involved in drug discovery, laboratory testing, medical diagnostics, point of care devices, or the pharmaceutical and semiconductor industries will have a vital interest in keeping abreast of the fast-moving developments in the microarray biochip business.

This report from BCC focuses on three of the emerging "stars" of biotechnology: genomics (including proteomics, pharmacogenomics and bioinformatics), gene therapy, antisense drugs and antibodies. Market estimates are provided for genomics, proteomics, pharmacogenomics, bioinformatics, gene therapy treatments for cancer and for other disorders, antisense drugs and antibodies. The forecast period is 1999 to 2005, and the scope of the market is worldwide. A detailed discussion and analysis of the effect of these products on the treatment of disease and the overall health care market are provided, along with comparative profiles of leading and emerging companies in the areas covered in this report.

This updated BCC report assesses the impact of new technology and new products on diseases and disorders that affect mainly women. The report addresses issues that are shaping the women's disorders market, and demographics that are influencing the market. The report focuses on the various pharmaceutical therapeutic/diagnostic preparations. Market size for products that are currently available and new entrants, and market size for potential products being developed for women's disorders are addressed. Markets are divided according to type of disorder, including Autoimmune Diseases and Diagnostics, Cancer, Gynecological Diseases and Infections, Kidney and Urological Diseases and Conditions, Menopause, Reproductive-related Therapeutics, Osteoporosis, Rheumatoid Arthritis, and Sexual Dysfunction. Patient populations and market estimates, as well as growth rates, are presented for 1998, 1999 and 2005. Competitor market shares and profiles are provided for leading companies currently active in the market.

Apoptosis, which is self-initiated cell death, is receiving considerable attention in biological and pharmaceutical research. Drugs that manipulate this process have extraordinary therapeutic potential: initiating apoptosis in tumor cells may retard cancer progression, while stopping it may slow the progression of diseases like Alzheimer's. Because apoptosis research is a relatively new field, new discoveries are reported frequently, and there is great potential for commercial applications. This report discusses pharmaceutical applications of apoptosis, as well as commercial opportunities in kits and reagents for studying the process. It also analyzes the latest research on the subject, and forecasts worldwide sales of drugs, kits and reagents. The report also lists companies and products in the apoptosis research reagents market, as well as a listing of pharmaceutical companies developing therapeutic agents that modulate apoptosis.

This BCC report is an in-depth analysis of the markets for media, sera and reagents in biotechnology and an update of the BCC report published in 1995. Media, sera and reagents are the most fundamental ingredients of research into the workings of mammalian cells and tissues, and as such are considered vital to the health of the whole biotechnology industry. The effect of increased focus on developing gene therapy approaches to various diseases and the advent of innovations such as organ culture, among others, will create new areas of demand for media, sera and reagents. As we enter the new century and the rate of development in biotechnology increases as never before, the time is ripe for the study of changes in the media, sera and reagent markets.

This technical/marketing report updates a previous BCC, Inc. study on commercial essential amino acids. Further, the study examines the current state of the commercial essential amino acid business, and presents an in-depth analysis that forecasts and tracks significant changes in the marketplace and identifies those amino acids with current or potentially greater commercial significance

The manufacture of protein drugs, being the interface between laboratory discovery and product sales, requires the solution of numerous problems. This new BCC study looks at all facets of protein drug manufacture, including lab vs. commercial production, choice of method, scale-up, upstream manipulation and more, and addresses important issues such as glycosylation, contamination and regulations. The report covers source extraction, fermentation, cell culture, chemical synthesis, and transgenic animals, as well as down-stream processing, including purification and formulation, and quantifying the input materials for protein drug production. Five-year market projections are given. Included in this report are relevant issues concerning technology transfer and patents, as well as profiles of established and emerging new protein drug companies.

Genomics is quietly transforming the pharmaceutical industry. Companies are moving from drug discovery and development based on medicinal chemistry to designing and developing drugs based on information provided by genomics. Virtually all the major pharmaceutical houses have formed partnerships with genomics firms that began to emerge in the early 1990s or created genomics divisions in-house. The reason for this rapid interest in genomics is simple: genomics allows greater efficiency in identifying therapeutic targets by determining which genes are responsible for the creation or enabling of disease processes, how these genes control these processes and what might be done to stop them. The discovery process involves studying genes that are expressed in diseased tissue, comparing them with gene expression in normal tissue and developing therapies to block the action of genes and gene products found only in diseased tissue. This report analyzes key technical activity directions and developments in bioinformatics, gene mapping, gene sequencing and expression, and measures potential markets in therapeutic and diagnostics for human and agricultural applications. Industry structure, human activities, and government involvement are detailed. A comprehensive analysis of who is doing how much of what is presented.

This report is an overview of the chiral technology industry as it stands in 1999. Chiral compounds are compounds that have both right-handed and left-handed forms. For many purposes, such as in medicine, one form is more effective than the other. It is then desirable to either synthesize one form, or separate the two forms. This report discusses methods of synthesis and separation. Leading companies in all areas of chiral technology are analyzed. Government regulation patents, leading universities and researchers are discussed. The report also explores different types of chiral drugs.

Monoclonal antibodies are on the cusp of significant commercial growth, now that major technical obstacles are being surmounted. Polyclonal antibodies also are making significant contributions due to new developments taking place there as well. This new study from BCC profiles the major players; analyzes product sales; and examines human therapeutic and in vivo diagnostic imaging applications including cancer, cardiovascular disease, infectious and immune diseases and others. Advances in technology and manufacturing capabilities for both polyclonal and monoclonal antibodies are also reviewed.